●Triple-Target Design: Unlike single-agonists (e.g., Semaglutide), Retatrutide's multi-receptor action enhances metabolic flexibility.
●Hybrid Structure: A modified peptide backbone with prolonged half-life, reducing dosing frequency.
●Tissue-Selective Activation: Optimized to minimize catabolic effects on muscle during caloric deficits.
